Vitamin D and prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 76, Issue 1-5, 2001, Pages 125-134

  Tuohimaa, P ^a,b   Lyakhovich, A ^a   Aksenov, N ^a   Pennanen, P ^a   Syvala H ^a   Lou, Y R ^a   Ahonen, M ^a   Hasan, T ^b   Pasanen, P ^c   Blauer M ^a   Manninen, T ^a   Miettinen, S ^a   Vilja, P ^a   Ylikomi, T ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Differentiation; Full spectrum light; Growth; Prevention; Prostate cancer; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; KERATINOCYTE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; OXYGENASE; STEROID 24 HYDROXYLASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UROCANIC ACID; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AUTOREGULATION; CANCER PREVENTION; CANCER RISK; CARCINOMA CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PROSTATE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ADULT; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CYTOCHROME P-450 CYP27A1; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATE; PROSTATIC NEOPLASMS; RATS; RNA, MESSENGER; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 0034986248     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00141-2     Document Type: Conference Paper

References (43)

1. Cancer statistics
2. Cancer incidence in Finland 1996 and 1997
3. Carcinoma of the prostate
4. Sunlight - Can it prevent as well as cause cancer?
5. Evidence of alteration of the vitamin D-endocrine system in blacks
6. Vitamin D and prostate cancer
7. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis)
8. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
9. Vitamin D and prostate cancer: A prediagnostic study with stored sera
10. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
11. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
12. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
13. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
14. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
15. Urocanic acid photochemistry and photobiology
16. Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential
17. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
18. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cancer cells
19. Localization of 1,25-dihydroxyvitamin D3 Receptor (VDR) expression in human prostate
20. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
21. 1α,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
22. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate
23. A non-invasive chamber sampling technique for HPLC analysis of human epidermal urocanic acid isomers
24. Quantitative immunoelectron microscopic analysis of the localization and induction of 25-hydroxy D3 24-hydroxylase in rat kidney
25. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder
26. Vitamin D induced upregulation of keratinocyte growth factor (KGF/FGF-7) in MCF-7 human breast cancer cells
27. The role of vitamin D endocrine system in health and disease
28. Quantitative mapping of amplicon structure by array CGH indentifies CYP24 as a candidate oncogene
29. Human prostate cells synthetize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3
30. Vitamin D receptor expression, 24-hydroxylase expression, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines
31. The 25-hydroxyvitamin D 24-hydroxylase
32. Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31
33. Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by the ligands1
34. 1α,25-Dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent
35. Rapid biological responses mediated by 1α,25-dihydroxyvitamin D3: A case study of transcaltachia (rapid hormonal stimulation of intestinal calcium transport)
36. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells
37. 1α,25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor (2 release
38. 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: Effect of vitamin D receptor regulation and potency of vitamin D3 analogs
39. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines
40. Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol
41. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice
42. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1α,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer